NEW YORK (GenomeWeb News) – Protagen said today that it has entered a collaboration agreement with Pfizer to use its SeroTag technology to identify biomarkers in support of Pfizer's drug development work.

Specifically, the collaboration aims to identify markers for stratifying patient cohorts or predicting patient response to a novel autoimmune disease drug being developed by Pfizer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.